LTX-109 gel, 3% w/w

DRUG2 trials

Sponsors

Pharma Holdings AS

Conditions

Hidradenitis SuppurativaNasal Decolonization of Staphylococcus Aureus

Phase 1

LTX-109 as Treatment for Hidradenitis Suppurativa

CompletedNCT04756336

Pharma Holdings ASHidradenitis Suppurativa

Start: 2021-03-05End: 2021-07-01Updated: 2021-08-30

A Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of Staphylococcus

CompletedNCT04767321

Pharma Holdings ASNasal Decolonization of Staphylococcus Aureus

Start: 2021-02-22End: 2021-06-01Updated: 2021-08-30